Table 4.
Probability of pharmacodynamic target attainment
| C. albicans | C. glabrata | C. krusei | C. parapsilosis | C. tropicalis | A. fumigatus | A. niger | A. terreus | ||
|---|---|---|---|---|---|---|---|---|---|
| Pfizer | |||||||||
| 4 mg/kg q12h | fAUC/MIC >25 | 99.9 | 86.3 | 97.9 | 99.5 | 99.6 | 97.1 | ||
| fAUC/MIC >35 | 99.8 | 81.6 | 94.8 | 99.2 | 99.3 | 92.8 | |||
| 6 mg/kg q12h | fAUC/MIC >25 | 99.9 | 90.0 | 99.1 | 99.7 | 99.8 | 99.2 | ||
| fAUC/MIC >35 | 99.8 | 86.8 | 98.3 | 99.6 | 99.6 | 97.9 | |||
| EUCAST | |||||||||
| 4 mg/kg q12h | fAUC/MIC >25 | 99.2 | 90.3 | 77.2 | 60.5 | ||||
| fAUC/MIC >35 | 99.1 | 80.3 | 61.9 | 41.6 | |||||
| 6 mg/kg q12h | fAUC/MIC >25 | 99.4 | 96.3 | 91.7 | 81.4 | ||||
| fAUC/MIC >35 | 99.2 | 92.1 | 80.3 | 65.4 | |||||
| 8 mg/kg q12h | fAUC/MIC >25 | 96.4 | 89.5 | ||||||
| fAUC/MIC >35 | 90.6 | 79.0 | |||||||
| 10 mg/kg q12h | fAUC/MIC >25 | 98.6 | 94.1 | ||||||
| fAUC/MIC >35 | 95.4 | 86.1 | |||||||
| 12 mg/kg q12h | fAUC/MIC >25 | 96.6 | |||||||
| fAUC/MIC >35 | 90.6 | ||||||||
| CLSI | |||||||||
| 4 mg/kg q12h | fAUC/MIC >25 | 99.1 | 89.1 | 94.1 | 99.6 | 98.0 | |||
| fAUC/MIC >35 | 99.0 | 86.0 | 88.1 | 99.3 | 97.7 | ||||
| 6 mg/kg q12h | fAUC/MIC >25 | 99.6 | 92.9 | 98.0 | 99.7 | 98.0 | |||
| fAUC/MIC >35 | 99.5 | 89.9 | 95.3 | 99.6 | 97.9 |
Data reported as % of patients obtaining target fAUC/MIC ratio at the prescribed dose. Data not available for every organism within all databases. fAUC0-12, free area under the concentration-time curve from 0 to 12 hours; MIC, minimum inhibitory concentration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; CLSI, Clinical and Laboratory Standards Institute.